Ubiquitin-specific protease 22: A novel molecular biomarker in glioma prognosis and therapeutics

Medical Oncology

Volumn 31, Issue 4, 2014, Pages

  Liang, Jun ^a   Zhang, Xianli ^a   Xie, Shao ^a   Zhou, Xiuping ^a   Shi, Qiong ^a   Hu, Jinxia ^a   Wang, Weifeng ^a   Qi, Weifeng ^a   Yu, Rutong ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Glioma; Prognosis; Ubiquitin specific protease 22 (USP22)

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEINASE; TUMOR MARKER; UBIQUITIN SPECIFIC PROTEASE 22; UNCLASSIFIED DRUG; THIOL ESTER HYDROLASE; USP22 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WESTERN BLOTTING; AGED; BRAIN; BRAIN TUMOR; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; TREATMENT OUTCOME;

AGED; BRAIN; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; THIOLESTER HYDROLASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84894263893     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0899-2     Document Type: Article

References (30)

1. Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet. 2003;361(9354):323-31.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507.
3. Buckner JC, Brown PD, O'Neill BP, et al. Central nervous system tumors. Mayo Clin Proc. 2007;82(10):1271-86.
4. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-89.
5. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet. 2001;2(2):120-9.
6. Donato V, Monaco A, Rollo A, et al. Elderly and poor prognosis patients with high grade glioma: hypofractionated radiotherapy. Clin Ter. 2007;158(3):227-30.
7. Rampling R, James A, Papanastassiou V. The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. J Neurol Neurosurg Psychiatry. 2004;75(Suppl 2):ii24-30.
8. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature. 2009;458(7237):438-44.
9. Lee HJ, Kim MS, Shin JM, et al. The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns. 2006;6(3):277-84.
10. Zhang XY, Varthi M, Sykes SM, et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 2008;29(1):102-11.
11. Zhang XY, Pfeiffer HK, Thorne AW, et al. USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle. 2008;7(11):1522-4.
12. Bouchard C, Dittrich O, Kiermaier A, et al. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. 2001;15(16):2042-7.
13. Liu YL, Yang YM, Xu H, et al. Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. J Surg Oncol. 2011;103(3):283-9.
14. Liu YL, Yang YM, Xu H, et al. Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol. 2010;25(11):1800-5.
15. Zhang Y, Yao L, Zhang X, Ji H, et al. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol. 2011;137(8):1245-53.
16. Lv L, Xiao XY, Gu ZH, et al. Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem. 2011;346(1-2):11-21.
17. Atanassov BS, Dent SY. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep. 2011;12(9):924-30.
18. Chipumuro E, Henriksen MA. The ubiquitin hydrolase USP22 contributes to 3end processing of JAK-STAT-inducible genes. FASEB J. 2012;26(2):842-54.
19. Liu YL, Jiang SX, Yang YM, et al. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys. 2012;62(1):229-35.
20. Zhao Y, Lang G, Ito S, et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell. 2008;29(1):92-101.
21. Yang M, Liu YD, Wang YY, et al. Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics. Tumour Biol. 2014;35(2):929-934.
22. Ling SB, Sun DG, Tang B, et al. Knock-down of USP22 by small interfering RNA interference inhibits HepG2 cell proliferation and induces cell cycle arrest. Cell Mol Biol (Noisy-le-grand). 2012;58(Suppl):OL1803-8.
23. Xu H, Liu YL, Yang YM, et al. Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth. Int J Colorectal Dis. 2012;27(1):21-30.
24. Li ZH, Yu Y, Du C, et al. RNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest. Oncol Lett. 2013;5(4):1290-4.
25. Yang DD, Cui BB, Sun LY, et al. The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma. Cell Biochem Biophys. 2011;61(3):703-10.
26. Vlachostergios PJ, Papandreou CN. The Bmi-1/NF-kappaB/VEGF story: another hint for proteasome involvement in glioma angiogenesis? J Cell Commun Signal. 2013;7(4):235-7.
27. Li Y, Hu J, Guan F, et al. Copper induces cellular senescence in human glioblastoma multiforme cells through downregulation of Bmi-1. Oncol Rep. 2013;29(5):1805-10.
28. Jiang L, Song L, Wu J, et al. Bmi-1 promotes glioma angiogenesis by activating NF-kappaB signaling. PLoS One. 2013;8(1):e55527.
29. Hu J, Liu YL, Piao SL, et al. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer. Lung Cancer. 2012;77(3):593-9.
30. Liu Y, Yang Y, Xu H, et al. Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. Diagn Mol Pathol. 2010;19(4):194-200.